Biocon signs agreement with Biomm for generic Semaglutide commercialisation in Brazil
India, April 19 -- Bengaluru-based biopharmaceutical firm Biocon hasannounced the signing of an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialisation of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes.
Under the terms of this agreement, Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialisation in the Brazilian market.
Biomm is Brazil's first and only biotechnology focused company, providing high quality healthcare to patients with chronic conditions and enhancing ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.